Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Actuarialon Mar 24, 2018 9:14pm
93 Views
Post# 27776631

RE:ATE Longs: Read posts carefully!

RE:ATE Longs: Read posts carefully!https://www.forbes.com/sites/matthewherper/2016/11/13/controversial-study-of-celebrex-raises-concerns-about-naproxen-ibuprofen/#6fc596095646

FitzGerald makes several points about Precision, which he says should be called Imprecision, aside from its ability to keep patients from stopping their medicines. First, he argues, it’s not a fair fight: the 200-milligram dose of Celebrex used in the study is less effective and has fewer side effects than the doses of the other drugs: 852 mg, on average, for naproxen and 2,045 mg for ibuprofen. (Over-the-counter doses are 660 mg and 1200 mg, respectively; Bayer says 80% of patients take less than 440 mg of Aleve a day.)

Also, FitzGerald argues, naproxen and ibuprofen can interfere with the function of aspirin, which prevents heart attacks, while Celebrex doesn’t. Nissen says analyses of his data don’t show that, but they only include whether patients were taking Aleve at the start of the study
Bullboard Posts